Bangalore-based.🧬 bio-founders.🛠️ open-source builders. 🧪 researchers. 🧠 thinkers, investors, and tinkerers . this is the event for you! . Come hang out on 26 July!. Reach out to @Vaibhavsai17 for more details.Sign up @

Bio-nerds & builders in #Bangalore!.We’re hosting a BioBuilders Meetup for folks building in Biology. Founders, researchers, open-source tinkerers, VCs this is for you. Let’s connect, share, and build. Register here: #techbio #syntheticbiology #deeptech.

AI-native thinking isn’t just software—it’s rewriting the biology stack. Building on @b2venture's TechBio ecosystem (S/O Marisa Krummrich) we mapped 500 + startups that are engineering this next-gen layer of programmable biology 🧵⬇️

🚀 Big news from Altitude Lab.We're thrilled to welcome Bioparin and Eyescreen to our growing community of game-changing startups. 💥🧬 #TechBio #Startups #Biotech

📢Techbio Startup Founders! Are you an emerging #techbio startup founder looking for support as you take the next step with your science. Apply to #DriveLifeSciences – MassBio’s 8-week program by June 20:

Best friends for 27 years. Met on first day at MIT. Phil is professor of computational biology at U. Toronto, and founder of two TechBio startups.

Photos from the event earlier this week with @valence_ai, @RecursionPharma, and @nvidia. Thanks to everyone for coming out! Always great to connect with the TechBio community at #NeurIPS2024. I'll be at workshops with the rest of the Valence team. We're hiring! Let's chat👇

We heard from some #DriveLifeSciences alumni at this week's #BIO2025. The 8-week program helped support their growing companies in Massachusetts. There's still time for #techbio startups to apply - the application deadline is noon ET on June 23!

Just under a week to go until the return of BIA’s TechBio X in 📍#Cambridge! ➡️ We’re thrilled to welcome Adam Cribbs, CTO of Entelo Bio, and Faye Rodgers, Bioinformatician at Constructive Bio, who will be speaking as part of the Innovator Showcases:

We’re bringing together biotech innovators, researchers, founders, and builders at the TechBio Berkeley Meetup on Tuesday, July 22, from 5:30–7:30 PM in the SF Bay Area🍻

📢 Calling all experienced #techbio professionals!. MassBio's Drive program is seeking passionate, experienced techbio professionals to become mentors to guide and support emerging startups in the #lifesciences. Learn more and apply: #DriveLifeSciences

This tree growing on a power line is the sign you've been waiting for to start building in the techbio space

This is more of the techbio ecosystem than we might like to admit

Leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer, Caris Life Sciences Inc., sets terms for its #IPO. Shares: 23.5 million.Price Range: $16.00-$18.00.Market Cap: $4.8b-$5.35b.Trade Date: Wednesday, 6/18. Link to $CAI S-1/A:

Recently, @StrongReporter, host of the SHIFT podcast, visited Recursion’s Salt Lake City headquarters to get a “peek behind the curtain” at our automated labs in action. She talked with cofounder and CEO @RecursionChris about the recent explosion of TechBio companies, biology’s

Our annual #AlignSummit25 is returning this year on October 7 at the Boston Marriott Copley Place. The startup presenter application for the three tracks (next generation therapies and #techbio) is open now through June 20. Apply to present:

$RXRX currently at it's all time lows 👀. $RXRX and MIT’s release of Boltz-2, an open-source AI model for drug discovery, is a significant step forward for Recursion Pharmaceuticals. Here’s how this impacts their business: . Revenue Overview: . Recursion, a TechBio company,

We just announced our Q4 and FY2024 financial results. It has been a momentous year for @RecursionPharma and the TechBio industry, with a number of critical factors now converging to allow us to rapidly accelerate our efforts to transform drug discovery and development. Across

Saving the really hard problems for humans. Speaking at @googlecloud's life-sciences roundtable last week, Recursion CTO @bmabey shared how TechBio companies are uniquely positioned to capitalize on AI agents. As reported by Brian Buntz in R&D World, Recursion leverages complex